|79.36||+0.3400||+0.43%||Vol 5.59M||1Y Perf -10.16%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.26 -0.33%|
|Target Price||84.31||Analyst Rating||Moderate Buy 1.95|
|Potential %||6.24||Finscreener Ranking||★+ 43.05|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★ 41.96|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★+ 53.64|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||★★ 39.98|
|Price Range Ratio 52W %||38.49||Earnings Rating||Sell|
|Market Cap||98.89B||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.91|
|EPS Growth Next 5 Years %||11.30|
|Avg. Weekly Volume||6.46M|
|Avg. Monthly Volume||6.20M|
|Avg. Quarterly Volume||5.39M|
Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 79.36 per share at the end of the most recent trading day (a 0.43% change compared to the prior day closing price) with a volume of 5.59M shares and market capitalization of 98.89B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11800 people. Gilead Sciences Inc. CEO is Daniel O'Day.
The one-year performance of Gilead Sciences Inc. stock is -10.16%, while year-to-date (YTD) performance is -7.56%. GILD stock has a five-year performance of 16.45%. Its 52-week range is between 72.8659 and 89.74, which gives GILD stock a 52-week price range ratio of 38.49%
Gilead Sciences Inc. currently has a PE ratio of 33.20, a price-to-book (PB) ratio of 5.24, a price-to-sale (PS) ratio of 5.37, a price to cashflow ratio of 11.40, a PEG ratio of 2.94, a ROA of 5.58%, a ROC of 8.43% and a ROE of 16.98%. The company’s profit margin is 14.74%, its EBITDA margin is 28.00%, and its revenue ttm is $19.89 Billion , which makes it $15.86 revenue per share.
Of the last four earnings reports from Gilead Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.91 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Moderate Buy (1.95), with a target price of $84.31, which is +6.24% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Gilead Sciences Inc. has a dividend yield of 3.43% with a dividend per share of $2.92 and a payout ratio of 67.00%.
Gilead Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.44, ATR14 : 1.40, CCI20 : 105.75, Chaikin Money Flow : 0.28, MACD : 0.02, Money Flow Index : 72.72, ROC : 6.04, RSI : 60.09, STOCH (14,3) : 95.18, STOCH RSI : 1.00, UO : 72.67, Williams %R : -4.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew D. Dickinson (Option Excercise at a value of $0), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $0), Dickinson Andrew (Sold 0 shares of value $0 ), Dickinson Andrew (Sold 5 000 shares of value $400 000 ), Dickinson Andrew D (Sold 5 000 shares of value $400 000 ), GILEAD SCIENCES, INC. (Buy at a value of $30 443 362), Johanna Mercier (Option Excercise at a value of $0), Kevin E. Lofton (Option Excercise at a value of $442 192), Lofton Kevin (Option Excercise at a value of $442 192), Mercier Johanna (Sold 0 shares of value $0 ), Merdad V. Parsey (Option Excercise at a value of $0), Merdad V. Parsey (Sold 22 649 shares of value $1 799 064 ), O'Day Daniel (Sold 0 shares of value $0 ), Parsey Merdad (Sold 1 485 shares of value $114 197 ), Patterson Sandra (Sold 0 shares of value $0 ), Sandra Patterson (Option Excercise at a value of $0), Telman Deborah (Sold 0 shares of value $0 )
Fri, 10 Nov 2023 20:11 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Vertex (VERX)- TipRanks. All rights reserved.
Tue, 26 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 26th- TipRanks. All rights reserved.
Sun, 10 Sep 2023 11:45 GMT Gilead presents early data from Phase 2 EVOKE-02 study- TipRanks. All rights reserved.
Thu, 17 Aug 2023 09:31 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and CVS Health (CVS)- TipRanks. All rights reserved.
Wed, 09 Aug 2023 02:25 GMT Gilead Sciences (GILD) Receives a Buy from Truist Financial- TipRanks. All rights reserved.
Mon, 24 Jul 2023 13:10 GMT Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Becton Dickinson (BDX)- TipRanks. All rights reserved.
Thu, 13 Jul 2023 11:31 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN)- TipRanks. All rights reserved.
Wed, 05 Jul 2023 12:05 GMT Gilead Sciences (GILD) Gets a Buy from Jefferies- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.